Tumor antigens BFA5 for prevention and/or treatment of cancer

Details for Australian Patent Application No. 2004230328 (hide)

Owner Aventis Pasteur, Ltd.

Inventors Berinstein, Neil; Gallichan, Scott; Parrington, Mark; Radvanyi, Laszlo; Lovitt, Corey; Pedyczak, Artur; Singh-Sandhu, Devender

Agent Spruson & Ferguson

Pub. Number AU-A-2004230328

PCT Pub. Number WO2004/092212

Priority 60/462,945 15.04.03 US

Filing date 15 April 2004

Wipo publication date 28 October 2004

International Classifications

C07K 014/47 Peptides having more than 20 amino acids

Event Publications

10 November 2005 PCT application entered the National Phase

  PCT publication WO2004/092212 Priority application(s): WO2004/092212

17 November 2005 Change of Name(s) of Applicant(s), Section 104

  Aventis Pasteur, Ltd The name of the applicant has been changed to Sanofi Pasteur Limited

13 October 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004230360-Porous film of vinylidene fluoride resin and method for producing same

2004230326-Method for synthesising 5-chloro-1-aryl-4-(4, 5-dicyano-1H-imidazol-2-yl)-3-alkyl-1Hpyrazole derivatives